Status:

COMPLETED

Hydrolyzed Fish Cartilage Effect on Knee Joint Functionality and Discomfort in Adult Population

Lead Sponsor:

Abyss Ingredients

Collaborating Sponsors:

Artialis

Conditions:

Knee Discomfort

Eligibility:

All Genders

40-80 years

Phase:

NA

Brief Summary

This study is an exploratory, non-comparative, multi-centric trial in 30 free-living healthy male and female subjects with moderate knee joint discomfort and loss of functionality. The objective of t...

Detailed Description

30 patients will be enrolled during a 4-month period in 3 investigational sites and each patient will undergo 3 visits (V0: Inclusion visit at baseline, V1: Follow-Up Visit after 1 month ± 3 day and V...

Eligibility Criteria

Inclusion

  • Male or female
  • Age limits (see above)
  • Body Mass Index BMI ≤ 35 kg/m2
  • Knee discomfort score at rest over the last 24 hours on the most painful knee evaluated on VAS (0-100) ≥ 40 at baseline
  • Able to follow the instructions of the study
  • Having signed an informed consent

Exclusion

  • related to knee:
  • Recent trauma (\< 1 month) of the knee responsible of the symptomatic knee;
  • Concurrent articular disease interfering with the evaluation of knee pain left to the Investigator's discretion
  • Prosthesis in the target knee
  • related to treatments:
  • Analgesics to manage knee pain 24 hours before inclusion visit;
  • Corticosteroids injection in the target knee in the last month;
  • Hyaluronan injection in the target knee in the last 6 months;
  • Arthroscopy in the last 6 months
  • Oral corticotherapy ≥ 5mg/day (in Prednisolone equivalent) in the last 3 months;
  • Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) or dietary supplement, i.e., curcuma extract, chondroitin, glucosamine, diacerein or avocado-soya unsaponifiables int he last 3 months
  • Contraindications to Cartidyss: hypersensitivity or allergy to the product components (fish)
  • Treatments based on strontium ranelate, bisphosphonates, selective estrogen-receptor modulator (SERM) and parathormone (PTH) in the last 12 months
  • related to associated diseases :
  • Any severe, uncontrolled and limiting diseases left to the Investigator's discretion
  • Anticipated need for any surgical or other invasive procedure during the trial including prosthesis in the target knee
  • Anticipated need for any forbidden treatments during the trial
  • Swallowing disorder
  • Patient with widespread pain/depression (e.g. fibromyalgia)
  • related to patients:
  • Close collaborators to the investigational team, the study coordinator or to the Sponsor
  • Currently participating or having participated in another therapeutic clinical trial in the last 3 months
  • Under guardianship or judicial protection
  • Pregnancy, breastfeeding, planned conception, or premenopausal women without effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device), tubal ligation or hysterectomy

Key Trial Info

Start Date :

June 11 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 17 2020

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT04420091

Start Date

June 11 2020

End Date

December 17 2020

Last Update

January 6 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Centre medical Chant d'Oiseau

Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, Brussels Capital, Belgium, 1150

2

Hopital Princesse Paola, VIVALIA

Marche-en-Famenne, Belgium, 6900

Hydrolyzed Fish Cartilage Effect on Knee Joint Functionality and Discomfort in Adult Population | DecenTrialz